CD44 and plasma cell myeloma: Experimental models further confirm that the absence of CD44 weakens tumor-endothelial adhesion and reduces invasiveness, though not affecting proliferation, while injection of CD44-positive cells promotes bone metastasis and myeloma-like lesions in vivo [154].